株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

脊髄小脳失調症(SCA)- 市場洞察、疫学、市場予測 2028年

Spinocerebellar Ataxia (SCA) - Market Insights, Epidemiology and Market Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 773932
出版日 ページ情報 英文 118 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.06円で換算しております。
Back to Top
脊髄小脳失調症(SCA)- 市場洞察、疫学、市場予測 2028年 Spinocerebellar Ataxia (SCA) - Market Insights, Epidemiology and Market Forecast - 2028
出版日: 2019年09月01日 ページ情報: 英文 118 Pages
概要

主要7カ国の脊髄小脳失調症(SCA)の有病数は、2017年に42,043人、その市場規模は3,020万米ドルと推計されています。

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の脊髄小脳失調症(SCA)の疫学について調査し、疾患および市場の概要、全体および国別の有病数および診断数の推移と予測、アンメットニーズ、新薬および候補薬の概要、国別の市場規模、市場の成長要因および障壁などについてまとめています。

目次

第1章 重要洞察

第2章 脊髄小脳失調症(SCA)市場の概要

  • 市場シェアと分布状況(実績値)
  • 市場シェアと分布状況(予測値)

第3章 疾患の背景と概要

  • イントロダクション
  • 脊髄小脳失調症(SCA):病型別
    • 脊髄小脳失調症1型(SCA1)
    • 脊髄小脳失調症2型(SCA2)
    • 脊髄小脳失調症3型(SCA3)
    • 脊髄小脳失調症6型(SCA6)
    • 脊髄小脳失調症7型(SCA7)
  • 原因と危険因子
  • 歴史
  • 兆候と症状
  • 病態生理
  • 診断
  • バイオマーカー
    • 神経イメージングバイオマーカー
    • 眼球運動バイオマーカー
    • 生物学的バイオマーカー

第4章 疫学と患者人口

  • 主な調査結果
  • 主要7カ国の脊髄小脳失調症(SCA)の有病数

第5章 脊髄小脳失調症(SCA)の疫学分析:国別

  • 米国
    • 仮定と根拠
    • 総有病数
    • 総診断数
    • 診断数:病型別
  • 欧州5カ国
    • ドイツ
      • 総有病数
      • 総診断数
      • 診断数:病型別
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本

第6章 治療法

  • 潜在的な治療法
  • 米国のガイドライン
  • 欧州のガイドライン
  • 脊髄小脳失調症(SCA)の管理

第7章 アンメットニーズ

第8章 新薬

  • Troriluzole:Biohaven Pharmaceuticals
    • 製品説明
    • その他の開発活動
    • 臨床開発
    • 安全性と有効性
    • 製品プロファイル
  • Rovatirelin (KPS-0373): キッセイ薬品工業

第9章 その他の有望な候補薬

  • IB1001:IntraBio
    • 製品説明
    • その他の開発活動
    • 臨床開発
    • 製品プロファイル
  • Stemchymal:Steminent Biotherapeutics

第10章 脊髄小脳失調症(SCA):主要7カ国市場の分析

  • 主な調査結果
  • 主要7カ国の市場規模

第11章 米国市場の見通し

  • 米国の市場規模
    • 総市場規模
    • 市場規模:選択薬別

第12章 欧州5カ国市場の見通し

  • ドイツ
    • 総市場規模
    • 市場規模:選択薬別
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本

第13章 市場の成長要因

第14章 市場の障壁

第15章 付録

  • 報告方法

第16章 DelveInsightのサービス内容

第17章 免責事項

第18章 DelveInsightについて

図表

List of Tables

  • Table 1: SCA subtypes
  • Table 2: SCA subtypes with associated clinical signs
  • Table 3: Total Population of Spinocerebellar Ataxia in the 7MM (2017-2028)
  • Table 4: Total Prevalent Population of Spinocerebellar Ataxia in the United States (2017-2028)
  • Table 5: Total Diagnosed cases of Spinocerebellar Ataxia in the United States (2017-2028)
  • Table 6: Type-Specific Prevalence of Spinocerebellar Ataxia in the United States (2017-2028)
  • Table 7: Total Prevalent Population of Spinocerebellar Ataxia in Germany (2017-2028)
  • Table 8: Total Diagnosed cases of Spinocerebellar Ataxia in Germany (2017-2028)
  • Table 9: Type-Specific Prevalence of Spinocerebellar Ataxia in Germany (2017-2028)
  • Table 10: Total Prevalent Population of Spinocerebellar Ataxia in France (2017-2028)
  • Table 11: Total Diagnosed cases of Spinocerebellar Ataxia in France (2017-2028)
  • Table 12: Type-Specific Prevalence of Spinocerebellar Ataxia in France (2017-2028)
  • Table 13: Total Prevalent Population of Spinocerebellar Ataxia in Italy (2017-2028)
  • Table 14: Total Diagnosed cases of Spinocerebellar Ataxia in Italy (2017-2028)
  • Table 15: Type-Specific Prevalence of Spinocerebellar Ataxia in Italy (2017-2028)
  • Table 16: Total Prevalent Population of Spinocerebellar Ataxia in Spain (2017-2028)
  • Table 17: Total Diagnosed cases of Spinocerebellar Ataxia in Spain (2017-2028)
  • Table 18: Type-Specific Prevalence of Spinocerebellar Ataxia in Spain (2017-2028)
  • Table 19: Total Prevalent Population of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Table 20: Total Diagnosed cases of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Table 21: Type-Specific Prevalence of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Table 22: Total Prevalent Population of Spinocerebellar Ataxia in Japan (2017-2028)
  • Table 23: Total Diagnosed cases of Spinocerebellar Ataxia in Japan (2017-2028)
  • Table 24: Type-Specific Prevalence of Spinocerebellar Ataxia in Japan (2017-2028)
  • Table 25: Troriluzole ,Clinical Trial Description, 2019
  • Table 26: Rovatirelin ,Clinical Trial Description, 2019
  • Table 27: IB1001 ,Clinical Trial Description, 2019
  • Table 28: Stemchymal, Clinical Trial Description, 2019
  • Table 29: 7 Major Market Size of Spinocerebellar Ataxia in USD Million (2017-2028)
  • Table 30: United States Market Size of Spinocerebellar Ataxia in the US, USD Million (2017-2028)
  • Table 31: Market Size of Spinocerebellar Ataxia by Line of Therapies in the US, in USD Million (2017-2028)
  • Table 32: Market Size of Spinocerebellar Ataxia in Germany, in USD Million (2017-2028)
  • Table 33: Market Size of Spinocerebellar Ataxia by Line of Therapies in Germany, in USD Million (2017-2028)
  • Table 34: Market Size of Spinocerebellar Ataxia in France, in USD Million (2017-2028)
  • Table 35: Market Size of Spinocerebellar Ataxia by Line of Therapies in France, in USD Million (2017-2028)
  • Table 36: Market Size of Spinocerebellar Ataxia in Italy, in USD Million (2017-2028)
  • Table 37: Market Size of Spinocerebellar Ataxia by Line of Therapies in Italy, in USD Million (2017-2028)
  • Table 38: Market Size of Spinocerebellar Ataxia in Spain, in USD Million (2017-2028)
  • Table 39: Market Size of Spinocerebellar Ataxia by Line of Therapies in Spain, in USD Million (2017-2028)
  • Table 40: Market Size of Spinocerebellar Ataxia in the UK, in USD Million (2017-2028)
  • Table 41: Market Size of Spinocerebellar Ataxia by Line of Therapies in the UK, in USD Million (2017-2028)
  • Table 42: Market Size of Spinocerebellar Ataxia in Japan, in USD, Million (2017-2028)
  • Table 43: Market Size of Spinocerebellar Ataxia by Line of Therapies in Japan, in USD Million (2017-2028)

List of Figures

  • Figure 1: SCA subtypes overall prevalence
  • Figure 2: Repeat expansions that cause ataxia
  • Figure 3: Harding's classification of Spinocerebellar Ataxia, detailing the classification of SCA based on symptom presentation
  • Figure 4: Common disease mechanisms underlying SCAs.
  • Figure 5: Flowchart of molecular genetic diagnosis of SCAs
  • Figure 6: Total Prevalent Patient Population of Spinocerebellar Ataxia in the 7MM (2017-2028)
  • Figure 7: Total Prevalent Population of Spinocerebellar Ataxia in the United States (2017-2028)
  • Figure 8: Total Diagnosed cases of Spinocerebellar Ataxia in the United States (2017-2028)
  • Figure 9:Type-Specific Prevalence of Spinocerebellar Ataxia in the United States (2017-2028)
  • Figure 10: Total Prevalent Population of Spinocerebellar Ataxia in Germany (2017-2028)
  • Figure 11: Total Diagnosed cases of Spinocerebellar Ataxia in Germany (2017-2028)
  • Figure 12:Type-Specific Prevalence of Spinocerebellar Ataxia in Germany (2017-2028)
  • Figure 13: Total Prevalent Population of Spinocerebellar Ataxia in France (2017-2028)
  • Figure 14: Total Diagnosed cases of Spinocerebellar Ataxia in France (2017-2028)
  • Figure 15:Type-Specific Prevalence of Spinocerebellar Ataxia in France (2017-2028)
  • Figure 16: Total Prevalent Population of Spinocerebellar Ataxia in Italy (2017-2028)
  • Figure 17: Total Diagnosed cases of Spinocerebellar Ataxia in Italy (2017-2028)
  • Figure 18:Type-Specific Prevalence of Spinocerebellar Ataxia in Italy (2017-2028)
  • Figure 19: Total Prevalent Population of Spinocerebellar Ataxia in Spain (2017-2028)
  • Figure 20: Total Diagnosed cases of Spinocerebellar Ataxia in Spain (2017-2028)
  • Figure 21:Type-Specific Prevalence of Spinocerebellar Ataxia in Spain (2017-2028)
  • Figure 22: Total Prevalent Population of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Figure 23: Total Diagnosed cases of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Figure 24:Type-Specific Prevalence of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Figure 25: Total Prevalent Population of Spinocerebellar Ataxia in Japan (2017-2028)
  • Figure 26: Total Diagnosed cases of Spinocerebellar Ataxia in Japan (2017-2028)
  • Figure 27:Type-Specific Prevalence of Spinocerebellar Ataxia in Japan (2017-2028)
  • Figure 28: Unmet Needs of Spinocerebellar ataxia
  • Figure 29: 7 Major Market Size of Spinocerebellar Ataxia in USD Million (2017-2028)
  • Figure 30: Market Size of Spinocerebellar Ataxia in the United States, USD Millions (2017-2028)
  • Figure 31: Market Size of Spinocerebellar Ataxia by Line of Therapies in the US, in USD Million (2017-2028)
  • Figure 32: Market Size of Spinocerebellar Ataxia in Germany, USD Million (2017-2028)
  • Figure 33: Market Size of Spinocerebellar Ataxia by Line of Therapies, in Germany, in USD Million (2017-2028)
  • Figure 34: Market Size of Spinocerebellar Ataxia in France, USD Million (2017-2028)
  • Figure 35: Market Size of Spinocerebellar Ataxia by Line of Therapies, in France, in USD Million (2017-2028)
  • Figure 36: Market Size of Spinocerebellar Ataxia in Italy, USD Million (2017-2028)
  • Figure 37: Market Size of Spinocerebellar Ataxia by Line of Therapies in Italy, in USD Million (2017-2028)
  • Figure 38: Market Size of Spinocerebellar Ataxia in Spain, USD Million (2017-2028)
  • Figure 39: Market Size of Spinocerebellar Ataxia by Line of Therapies in Spain, in USD Million (2017-2028)
  • Figure 40: Market Size of Spinocerebellar Ataxia in the UK, USD Million (2017-2028)
  • Figure 41: Market Size of Spinocerebellar Ataxia by Line of Therapies in the UK, in USD Million (2017-2028)
  • Figure 42: Market Size of Spinocerebellar Ataxia in Japan, USD Million (2017-2028)
  • Figure 43: Market Size of Spinocerebellar Ataxia by Line of Therapies in Japan, in USD Million (2017-2028)
  • Figure 44: Market Drivers
  • Figure 45: Market Barriers
目次
Product Code: DIMI0470

DelveInsight's 'Spinocerebellar Ataxia (SCA) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of SCA in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Spinocerebellar Ataxia (SCA) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Spinocerebellar Ataxia (SCA) - Disease Understanding and Treatment Algorithm

Spinocerebellar Ataxia is a genetic disorder which is progressive, degenerative, and often fatal. The clinical marker of all SCAs is a progressive loss of balance and coordination accompanied by slurred speech. The mobility and communicative skills of individuals with an SCA are restricted, which strongly impairs quality of life, and many SCAs lead to premature death.

The DelveInsight Spinocerebellar Ataxia (SCA) market report gives the thorough understanding of the Spinocerebellar Ataxia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Spinocerebellar Ataxia in the US, Europe and Japan.

Spinocerebellar Ataxia Epidemiology

The Spinocerebellar Ataxia (SCA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total diagnosed cases of Spinocerebellar Ataxia and type-specific prevalent cases) scenario of Spinocerebellar Ataxia (SCA) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of prevalent cases of Spinocerebellar Ataxia (SCA) in 7 MM was found to be 42,043, in the year 2017.

Spinocerebellar Ataxia Drug Chapters

This segment of the Spinocerebellar Ataxia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The SCA market forecast provided in the report solely focuses on the market revenue generated by the pharmacological treatment (including off-label symptomatic therapies, such as Neuro-protective agents, Nicotine Receptor Agonists, Serotonergic Therapy, and GABAergic Therapy) used for SCA management in the diagnosed cases. Detailed chapter for upcoming therapies like Troriluzole (BHV-4157; Biohaven Pharmaceuticals) and KPS-0373 (Rovatirelin; Kissei Pharmaceuticals) have been covered in the report.

Spinocerebellar Ataxia Market Outlook

The Spinocerebellar Ataxia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Spinocerebellar Ataxia in 7MM was found to be USD 30.28 Million in 2017, and is expected to further increase during the course of the study period from 2017-2028. Among the 7MM, Japan accounts for the largest market size of Spinocerebellar Ataxia, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and the United States.

Spinocerebellar Ataxia Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Spinocerebellar Ataxia Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Spinocerebellar Ataxia Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Spinocerebellar Ataxia Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Spinocerebellar Ataxia market
  • Organize sales and marketing efforts by identifying the best opportunities for Spinocerebellar Ataxia market
  • To understand the future market competition in the Spinocerebellar Ataxia market.

Table of Contents

1. Key Insights

2. Spinocerebellar Ataxia Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Spinocerebellar Ataxia in 2017
  • 2.2. Market Share (%) Distribution of Spinocerebellar Ataxia in 2028

3. Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Subtypes of SCA
    • 3.2.1. SCA1
    • 3.2.2. SCA2
    • 3.2.3. SCA3
    • 3.2.4. SCA6
    • 3.2.5. SCA7
  • 3.3. Causes and risk factors
  • 3.4. History
  • 3.5. Signs and Symptoms
  • 3.6. Pathophysiology
  • 3.7. Diagnosis
  • 3.8. Biomarkers
    • 3.8.1. Neuroimaging biomarkers
    • 3.8.2. Oculomotor biomarkers
    • 3.8.3. Biological biomarkers

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Total Patient Population of Spinocerebellar Ataxia

5. Country Wise-Epidemiology of Spinocerebellar Ataxia

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Total Prevalent Population of Spinocerebellar Ataxia in the United States
    • 5.1.3. Total Diagnosed Cases of Spinocerebellar Ataxia in the United States
    • 5.1.4. Type-Specific Prevalence of Spinocerebellar Ataxia in the United States
  • 5.2. EU5 Countries
    • 5.2.1. Assumptions and Rationale
  • 5.3. Germany
    • 5.3.1. Total Prevalent Population of Spinocerebellar Ataxia in Germany
    • 5.3.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Germany
    • 5.3.3. Type-Specific Prevalence of Spinocerebellar Ataxia in the Germany
  • 5.4. France
    • 5.4.1. Total Prevalent Population of Spinocerebellar Ataxia in France
    • 5.4.2. Total Diagnosed Cases of Spinocerebellar Ataxia in France
    • 5.4.3. Type-Specific Prevalence of Spinocerebellar Ataxia in France
  • 5.5. Italy
    • 5.5.1. Total Prevalent Population of Spinocerebellar Ataxia in Italy
    • 5.5.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Italy
    • 5.5.3. Type-Specific Prevalence of Spinocerebellar Ataxia in Italy
  • 5.6. Spain
    • 5.6.1. Total Prevalent Population of Spinocerebellar Ataxia in Spain
    • 5.6.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Spain
    • 5.6.3. Type-Specific Prevalence of Spinocerebellar Ataxia in Spain
  • 5.7. United Kingdom
    • 5.7.1. Total Prevalent Population of Spinocerebellar Ataxia in the United Kingdom
    • 5.7.2. Total Diagnosed Cases of Spinocerebellar Ataxia in the United Kingdom
    • 5.7.3. Type-Specific Prevalence of Spinocerebellar Ataxia in the United Kingdom
  • 5.8. Japan
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Total Prevalent Population of Spinocerebellar Ataxia in Japan
    • 5.8.3. Total Diagnosed Cases of Spinocerebellar Ataxia in Japan
    • 5.8.4. Type-Specific Prevalence of Spinocerebellar Ataxia in the Japan

6. Treatments

  • 6.1. Potential treatments
  • 6.2. U.S. Guidelines
    • 6.2.1. Local Susceptibility of Host Tissue
  • 6.3. Europe Guidelines
  • 6.4. Management of Spinocerebellar Ataxia

7. Unmet Needs

8. Emerging Therapies

  • 8.1. Troriluzole: Biohaven Pharmaceuticals
    • 8.1.1. Product Description
    • 8.1.2. Other Development Activities
    • 8.1.3. Clinical Development
    • 8.1.4. Safety and Efficacy
    • 8.1.5. Product Profile
  • 8.2. Rovatirelin (KPS-0373): Kissei Pharmaceutical
    • 8.2.1. Product Description
    • 8.2.2. Clinical Development
    • 8.2.3. Safety and Efficacy
    • 8.2.4. Product Profile

9. Other Promising Candidates

  • 9.1. IB1001: IntraBio
    • 9.1.1. Product Description
    • 9.1.2. Other Development Activities
    • 9.1.3. Clinical Development
    • 9.1.4. Product Profile
  • 9.2. Stemchymal: Steminent Biotherapeutics
    • 9.2.1. Product Description
    • 9.2.2. Other Development Activities
    • 9.2.3. Clinical Development
    • 9.2.4. Safety and Efficacy
    • 9.2.5. Product Profile

10. Spinocerebellar Ataxia: 7 Major Market Analysis

  • 10.1. Key Findings
  • 10.2. Market Size of Spinocerebellar Ataxia in 7MM

11. The United States Market Outlook

  • 11.1. United States Market Size
    • 11.1.1. Total Market size of Spinocerebellar Ataxia
    • 11.1.2. Market Size by Line of Therapies

12. EU-5 Countries: Market Outlook

  • 12.1. Germany
    • 12.1.1. Total Market size of Spinocerebellar Ataxia in Germany
    • 12.1.2. Market Size by Line of Therapies
  • 12.2. France
    • 12.2.1. Total Market Size of Spinocerebellar Ataxia
    • 12.2.2. Market Size by Line of Therapies
  • 12.3. Italy
    • 12.3.1. Total Market Size of Spinocerebellar Ataxia
    • 12.3.2. Market Size by Line of Therapies
  • 12.4. Spain
    • 12.4.1. Total Market Size of Spinocerebellar Ataxia
    • 12.4.2. Market Size by Line of Therapies
  • 12.5. The United Kingdom
    • 12.5.1. Total Market Size of Spinocerebellar Ataxia
    • 12.5.2. Market Size by Line of Therapies
  • 12.6. Japan: Market Outlook
  • 12.7. Japan Market Size
    • 12.7.1. Total Market Size of Spinocerebellar Ataxia
    • 12.7.2. Market Size by Line of Therapies

13. Market Drivers

14. Market Barriers

15. Appendix

  • 15.1. Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

Back to Top